Ashlee Joseph

9PUBLICATIONS
76CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

|Apr 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Feb 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Dec 11, 2025
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Aug 05, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.

Zachary D Epstein-Peterson, Anath C Lionel, Ashlee Joseph

|Oct 22, 2024
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.

Anita Kumar, Jacob Soumerai, Jeremy S Abramson

Pageof 2

Frequent Collaborators

7 joint publications

Anita Kumar

5 joint publications

Andrew Zelenetz

4 joint publications

Christine E Ryan

4 joint publications

Gilles Salles